THRIVING: A randomised controlled trial assessing the efficacy of exercise versus a complementary therapy on the physical and psychosocial outcomes in haematological cancers post treatment

THRIVING: A randomised controlled trial assessing the efficacy of exercise versus a complementary therapy on physical and psychosocial outcomes in haematological cancers post treatment

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000450213

Acronym

THRIVING

Enrollment

150

Registered

2009-06-12

Start date

2009-08-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study assesses the efficacy of exercise versus a complementary therapy on the physical and psychosocial well-being of people who have undergone treatment for haematological malignancies. Who is it for? You can join this study if you are undergoing or due to complete treatment for non Hodgkin's lymphoma (NHL), Hodgkin's Lymphoma (HL) or Myeloma. Participants will be randomly divided into 3 groups. The groups will undertake 12 weeks of either exercise, Bowen therapy (a hands-on technique to enhance healing and relieve pain), or 'Wait-listed' supportive care. Participants will be assessed at 0 weeks (pre-), 12 weeks (mid), 24 weeks (post), and there will be the option of a 12 month follow-up. The study aims to measure key physiological and psychosocial outcomes following treatment including quality of life (QoL), anxiety, depression, fatigue, body composition, aerobic fitness and strength.

Interventions

Arm 1: 12 weeks best practice exercise (inc aerobic & resistance training, 3 x week, approximately 45min session including weight machines, walking, stationary cycling and rowing ergometry, self-directed sessions fully supervised by an exercise physiologist). Arm 2 - 12 weeks Bowen Therapy (1 x week approximately 30-45mins: Bowen therapy is a dynamic system of muscle and connective tissue therapy that utilises subtle inputs to the body to stimulate the body to heal itself).

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Undergoing or due to complete chemotherapy treatment for a Haematological cancer (Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma (HL) or myeloma); doctors approval; pass a pre-exercise screening; written consent

Exclusion criteria

have pre-existing cardiac disease or uncontrolled hypertension; unable to participate in a 12 week structured program; unable to understand the implications of their participation; currently engaged in a structed exercise or complementary therapy program; have undergone recent surgery which limits their ability to participate in exercise

Outcome results